New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
09:18 EDTJCP, UNXL, NDLS, DAR, CTRX, MYL, INO, RIG, WDAY, CIE, CTIC, TSLA, BIDU, BBY, CREEOn The Fly: Pre-market Movers
UP AFTER EARNINGS: J.C. Penney (JCP), up 25%... Best Buy (BBY), up 7%... Baidu (BIDU), up 2.7%... Workday (WDAY), up 6%... Mylan (MYL), up 3%... Transocean (RIG), up 1.3%. ALSO HIGHER: Cell Therapeutics (CTIC), up 8.5% after NICE published final guidance on Pixuvri... Tesla (TSLA), up 3% after announcing a $1.6B convertible note offering and outlining plans for its Gigafactory, which the company said is designed to reduce cell costs much faster... Cobalt (CIE), up 9.4% after reporting on Orca well potential. DOWN AFTER EARNINGS: Catamaran (CTRX), down 11%... Darling (DAR), down 9%... Babcock & Wilcox (BWC), down 7%... Noodles & Co (NDLS), down 7.7%... Uni-Pixel (UNXL), down 8.2%. ALSO LOWER: Cree (CREE), down 1.5% following Piper Jaffray downgrading shares after assuming coverage of stock.
News For JCP;BBY;BIDU;TSLA;CTIC;CIE;WDAY;RIG;INO;MYL;CTRX;DAR;NDLS;UNXL;CREE From The Last 14 Days
Check below for free stories on JCP;BBY;BIDU;TSLA;CTIC;CIE;WDAY;RIG;INO;MYL;CTRX;DAR;NDLS;UNXL;CREE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
August 8, 2014
09:37 EDTTSLAActive equity options trading on open
Subscribe for More Information
07:01 EDTMYLHarvard professor says Treasury can reduce inversion incentives, NY Times says
Subscribe for More Information
06:30 EDTMYLMylan downgraded to Sector Perform from Outperform at RBC Capital
Subscribe for More Information
August 7, 2014
17:12 EDTDARDarling reports Q2 adjusted EPS 24c, consensus 28c
Subscribe for More Information
16:35 EDTUNXLUni-Pixel reports Q2 EPS (49c), consensus (50c)
Subscribe for More Information
16:00 EDTTSLAOptions Update; August 7, 2014
Subscribe for More Information
10:29 EDTMYLMylan: Noise about inversion is tremendous speculation and that's all it is
Subscribe for More Information
10:23 EDTMYLMylan sees FY14 CapEx $350M-$400M
Subscribe for More Information
10:21 EDTRIGTransocean says pace of tendering is slow for deep water market
Subscribe for More Information
10:20 EDTMYLMylan sees FY14 adjusted EBITDA $2.2B-$2.4B
Subscribe for More Information
10:20 EDTMYLMylan says litigation ins ongoing in India regarding Teva
Mylan (MYL) said that it expects Teva's (TEVA) efforts to seek an injunction will "as ineffective as it was in U.S. courts." The company said it will not provide further comment on the matter. Mylan said it will also postpone its 2014 Investor Day due to the ongoing nature of the Abbott (ABT) transaction. It expects its fully realized savings and profit from new products will not be realized till 2015. Comments taken from Q2 earnings conference call.
09:36 EDTTSLAActive equity options trading on open
Subscribe for More Information
09:08 EDTRIG, CTICOn The Fly: Pre-market Movers
Subscribe for More Information
07:23 EDTJCPJ.C. Penney August volatility elevated into Q2 and outlook
Subscribe for More Information
06:42 EDTMYLObama to look to limit inversion deals, Politico says
Subscribe for More Information
06:37 EDTMYLMylan narrows FY14 adjusted EPS view to $3.25-$3.45 from $3.25-$3.60
Consensus $3.37. Narrows FY14 revenue guidance to $7.8B-$8B from $7.8B-$8.2B, consensus $7.77B.
06:36 EDTMYLMylan sees Q3 EPS 90c-95c, consensus $1.03
Subscribe for More Information
06:34 EDTMYLMylan reports Q2 adjusted EPS 69c, consensus 70c
Reports Q2 revenue $1.84B, consensus $1.88B.
06:07 EDTTSLATesla implied volatility of 40 at lower end of index mean range
Subscribe for More Information
05:44 EDTCTICCTI BioPharma announces Pacritinib granted fast track designation by FDA
CTI BioPharma announced that pacritinib has been granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy. Pacritinib is an oral tyrosine kinase inhibitor with dual activity against JAK2 and FLT3. The drug candidate is currently being evaluated in two Phase 3 clinical trials, known as the PERSIST program, for patients with myelofibrosis.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use